NorthX Biologics
Address: Storjordenvägen 2,, Matfors, 864 31About Us
We provide process development and manufacturing services with expertise in plasmids, proteins and other advanced biologics. NorthX Biologics sits in the heart of Sweden, and our team has been manufacturing biologics to GMP since 1992. In 2021 we were recognised as a national innovation hub for advanced therapeutics and vaccines.
Sectors
- Contract Research & Development
- Contract Manufacturing
- Collaborations & Partnerships- R&D
- Collaborations & Partnerships-Manufacture
- Collaborations & Partnerships-Services
Categories
- Biotechnology
- Biologics
- DNA-Synthetic
- Plasmid DNA
- Microbial Fermentation
- Proteins
- Antibodies-monoclonals
- Cell Line Development
- Proteins-Recombinant
- Messenger RNA
- Cell Banking
- Vaccine Manufacturing
- Liposomes
- Lipids
- Sterile Formulations
- Aseptic Processing
Certifications
- GMP- as per ICH Q7a
- GMP-Sweden-MPA-Inspected
- GMP-EU-EMA -Inspected
News
NorthX Biologics and Demeetra Announce Strategic Collaboration
NorthX Biologics and Demeetra today announced a strategic collaboration that combines a best-in-class, high-titer GS (−/−) CHO cell line with full freedom to operate—without additional IP-related costs. Together, the companies now offer an integrated solution spanning advanced cell line development (CLD), master cell banking (MCB), and GMP manufacturing services. The collaboration is designed to help biotech companies reach IND-enabling and clinical milestones faster by strengthening the parts of development that most often drive timelines and risk. By streamlining the path from gene to proof-of-concept, the partnership reduces technical setbacks and eliminates the need to rebuild cell lines or re-qualify processes when transitioning to a manufacturing partner.
NorthX Biologics Secures Significant Growth Investment from Signet Healthcare Partners
STOCKHOLM--(BUSINESS WIRE)-- NorthX Biologics, a leading Nordic biopharmaceutical Contract, Development and Manufacturing Organization (CDMO), is pleased to announce a significant growth investment from Signet Healthcare Partners (Signet), a U.S.-based healthcare private equity firm with deep expertise in pharmaceutical services. This strategic partnership will enable NorthX Biologics to accelerate its expansion plans, including enhancing facilities, broadening service lines, and extending U.S. commercial reach.
Amarna Therapeutics partners with NorthX Biologics to advance Nimvec™ AM510 gene therapy development
Amarna Therapeutics, a privately held biotechnology company specializing in transformative gene therapies, is pleased to announce its strategic collaboration with NorthX Biologics, a leading biologics manufacturing partner. This partnership represents a major step in advancing the clinical trial manufacturing of Nimvec™ AM510, Amarna’s groundbreaking gene therapy platform designed to transform the treatment of immune-mediated diseases. The collaboration will begin with the transfer of Amarna’s research-scale production process for Nimvec™ AM510 to NorthX Biologics. This critical step initiates the Chemistry, Manufacturing, and Controls (CMC) development process at NorthX, laying the groundwork for cGMP-compliant manufacturing to support First-in-Human (FiH) clinical trials. Together, the companies will focus on optimizing and scaling production processes to ensure high-quality, safe, and effective therapies for future clinical applications.
Neogap Therapeutics partners with NorthX Biologics
Neogap Therapeutics, a Swedish clinical-stage biotechnology company, has entered a strategic collaboration with NorthX Biologics, a leading CDMO, to advance manufacturing strategies for Neogap’s personalised cancer cell therapy. Supported by ongoing funding from the European Innovation Council (EIC) Accelerator, the partnership aims to optimise and scale production for future clinical trials.
Neogap Therapeutics develops pTTL (personalised Tumour Trained Lymphocytes), a cell therapy designed to treat solid tumours by training the immune system to recognise and attack cancer cells through the patient’s unique neoantigens. Currently, pTTL is under evaluation in a Phase I/II clinical trial focused on assessing its safety and tolerability in patients with advanced colorectal cancer.
Source: The Partnership Tree | https://www.pharmaservicesdirectory.com